Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06046560 · ClinicalTrials.gov registry record · Phase 4

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

A Phase 4 study of Diabetes and Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 4
Development phase
200
Enrollment target
1
Study location

NCT06046560: Completed Phase 4 study of Diabetes and Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.

NCT06046560 is a Phase 4 study of Diabetes and Cardiovascular Diseases that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 200 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06046560, a Phase 4 study of Diabetes and Cardiovascular Diseases, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.

Primary Outcome

Number of patients with prescriptions of SGLT2i or GLP1-RA at any time

Interventions

  • DRUG SGLT2 inhibitor, GLP-1 RA
  • BEHAVIORAL Education-First

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-03-22
Est. Completion 2023-07-25
Phase Phase 4
Brigham and Women's Hospital

937 total trials

What the finished NCT06046560 record still lists

NCT06046560 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which SGLT2 inhibitor, GLP-1 RA is the first listed.

NCT06046560 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06046560 about?

NCT06046560 is a clinical study titled "Diabetes Remote Intervention to improVe Use of Evidence-based Medications". A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications...

What is the current status of trial NCT06046560?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-03-22. Estimated completion is 2023-07-25.

What conditions does trial NCT06046560 study?

This clinical trial studies the following conditions: Diabetes, Cardiovascular Diseases.

What interventions are being tested in trial NCT06046560?

The interventions under investigation include: SGLT2 inhibitor, GLP-1 RA (DRUG), Education-First (BEHAVIORAL).

Who is sponsoring clinical trial NCT06046560?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06046560 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06046560's enrollment target sits among peer trials

200 147th of 338 higher than 186 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06046560, the US trial registry maintained by the National Library of Medicine. NCT06046560 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.